-+ 0.00%
-+ 0.00%
-+ 0.00%

Zentek subsidiary Triera completes Canadian H5N1 aptamer contract

PUBT·04/14/2026 12:33:14
Listen to the news
Zentek subsidiary Triera completes Canadian H5N1 aptamer contract
  • Zentek unit Triera Biosciences completed an Innovative Solutions Canada contract to develop an aptamer-based asset targeting H5N1 avian influenza.
  • Triera selected aptamer central to asset in about 7 weeks, highlighting rapid development versus conventional antibody approaches.
  • Ontario Centres of Innovation Collaborate 2 Commercialize agreement executed to fund next phase focused on proprietary seasonal influenza candidates.
  • OCI project budget totals about $300,000, funded through matched cash contributions from OCI and Zentek.
  • Program expands platform toward seasonal influenza targets including H1 and H3, with work run with McMaster University laboratories.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zentek Ltd. published the original content used to generate this news brief via Newsfile (Ref. ID: 202604140830NEWSFILECNPR____20260414_292366_1) on April 14, 2026, and is solely responsible for the information contained therein.